Nothing Special   »   [go: up one dir, main page]

You seem to have javascript disabled. Please note that many of the page functionalities won't work as expected without javascript enabled.
 
 
Sign in to use this feature.

Years

Between: -

Subjects

remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline

Journals

remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline

Article Types

Countries / Regions

remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline

Search Results (41,881)

Search Parameters:
Keywords = toxicity

Order results
Result details
Results per page
Select all
Export citation of selected articles as:
21 pages, 4816 KiB  
Article
Roscovitine, a CDK Inhibitor, Reduced Neuronal Toxicity of mHTT by Targeting HTT Phosphorylation at S1181 and S1201 In Vitro
by Hongshuai Liu, Ainsley McCollum, Asvini Krishnaprakash, Yuxiao Ouyang, Tianze Shi, Tamara Ratovitski, Mali Jiang, Wenzhen Duan, Christopher A. Ross and Jing Jin
Int. J. Mol. Sci. 2024, 25(22), 12315; https://doi.org/10.3390/ijms252212315 (registering DOI) - 16 Nov 2024
Abstract
Huntington’s disease (HD) is an autosomal dominant neurodegenerative disease caused by a single mutation in the huntingtin gene (HTT). Normal HTT has a CAG trinucleotide repeat at its N-terminal within the range of 36. However, once the CAG repeats exceed 37, the mutant [...] Read more.
Huntington’s disease (HD) is an autosomal dominant neurodegenerative disease caused by a single mutation in the huntingtin gene (HTT). Normal HTT has a CAG trinucleotide repeat at its N-terminal within the range of 36. However, once the CAG repeats exceed 37, the mutant gene (mHTT) will encode mutant HTT protein (mHTT), which results in neurodegeneration in the brain, specifically in the striatum and other brain regions. Since the mutation was discovered, there have been many research efforts to understand the mechanism and develop therapeutic strategies to treat HD. HTT is a large protein with many post-translational modification sites (PTMs) and can be modified by phosphorylation, acetylation, methylation, sumoylation, etc. Some modifications reduced mHTT toxicity both in cell and animal models of HD. We aimed to find the known kinase inhibitors that can modulate the toxicity of mHTT. We performed an in vitro kinase assay using HTT peptides, which bear different PTM sites identified by us previously. A total of 368 kinases were screened. Among those kinases, cyclin-dependent kinases (CDKs) affected the serine phosphorylation on the peptides that contain S1181 and S1201 of HTT. We explored the effect of CDK1 and CDK5 on the phosphorylation of these PTMs of HTT and found that CDK5 modified these two serine sites, while CDK5 knockdown reduced the phosphorylation of S1181 and S1201. Modifying these two serine sites altered the neuronal toxicity induced by mHTT. Roscovitine, a CDK inhibitor, reduced the p-S1181 and p-S1201 and had a protective effect against mHTT toxicity. We further investigated the feasibility of the use of roscovitine in HD mice. We confirmed that roscovitine penetrated the mouse brain by IP injection and inhibited CDK5 activity in the brains of HD mice. It is promising to move this study to in vivo for pre-clinical HD treatment. Full article
(This article belongs to the Section Molecular Neurobiology)
Show Figures

Figure 1

Figure 1
<p>Kinase assays identified upstream kinases modifying the serine of HTT peptides in vitro. In vitro kinase assay was used to screen the kinase targeting HTT peptide bearing serine 1181, serine 1201, and serine 2653 of HTT. (<b>A</b>) Kinases targeting the serine 1181 of the HTT peptide. (<b>B</b>) Kinases targeting the serine 1201 of the HTT peptide. (<b>C</b>) Kinases targeting the serine 2653 of the HTT peptide. CDK1 is highlighted by blue rectangles and CDK5/p25 by red rectangles. RBC, red blood cell substrate. Dotted lines indicate the 5% cut-off of enzyme activity used for the kinase screening.</p>
Full article ">Figure 2
<p>HTT peptides as potential as targets for CDKs. (<b>A</b>) The amino acid sequences surrounding serine of 1181, 1201, and 2653 of HTT from different species. S/T-P-x-K/R is a consensus site for both CDK1 and CDK5, which means that the amino acid of S or T followed by P-x-K/R could be phosphorylated by CDK1 and CDK5. (S = serine; T = threonine; P = proline; K = lysine; R = arginine; x is any amino acid). It is well conserved in vertebrates for S1181 and S1201 of the HTT sequence, but not S2653. (<b>B</b>) CDKs target serine 1181 of the HTT peptide. (<b>C</b>) CDKs target serine 1201 of HTT peptide. CDK1 is highlighted by blue rectangles and CDK5/p25 by red rectangles. RBC, red blood cell substrate. Dotted lines indicate the 1% cut-off of enzyme activity used for the kinase screening.</p>
Full article ">Figure 3
<p>The effect of knocking down CDK5 on the phosphorylation of S1181 and S1201 of mHTT. HEK293 cells were co-transfected with a plasmid expressing full-length mutant huntingtin with 82Q (FL-82Q) and siRNA targeting human CDK5 for 24 h. The expression level of CDK5, phosphorylated S1181-HTT (p-S1181), and phosphorylated S1201-HTT (p-S1201) were detected by western blot. (<b>A</b>) The representative western blot for CDK5. (<b>B</b>) The quantification of CDK5 expression. (<b>C</b>) The representative western blot for p-S1181-HTT. (<b>D</b>) The quantification of p-S1181-HTT expression. (<b>E</b>) The representative western blot for p-S1201-HTT. (<b>F</b>) The quantification of p-S1201-HTT expression. The experiment was repeated by at least two different analysts. Each experiment had <span class="html-italic">n</span> = 3. One representative experiment is presented. 2166 is the anti-HTT antibody (MAB2166, Millipore). RNAi = pooled siRNA targeting human CDK5. A two-tailed Student <span class="html-italic">t</span>-test was used. * <span class="html-italic">p</span> &lt; 0.05; ** <span class="html-italic">p</span> &lt; 0.01.</p>
Full article ">Figure 4
<p>The effect of CDK5 overexpression on S1181 of mHTT. HEK293 cells were co-transfected with HTT plasmid FL-82Q and a plasmid expressing human CDK5 for 24 h. The expression levels of CDK5, p-S1181, and p-S1201 were detected by western blot. (<b>A</b>) The representative western blot for CDK5, p-S1181, 2166, and MW1. (<b>B</b>) The quantification of CDK5 expression. (<b>C</b>,<b>D</b>) The quantification of p-S1181 expression. (<b>E</b>) The quantification of total huntingtin (MAB2166) expression. (<b>F</b>) The quantification of mutant huntingtin (MW1) expression. The experiment was repeated by at least two different analysts. Each experiment had n = 3. One representative experiment is presented. 2166 is the anti-HTT antibody (MAB2166). MW1 is the anti-HTT antibody that binds to mutant huntingtin (clone MW1). RNAi = siRNA targeting human CDK5. A two-tailed Student <span class="html-italic">t</span>-test was used. ** <span class="html-italic">p</span> &lt; 0.01; *** <span class="html-italic">p</span> &lt; 0.001.</p>
Full article ">Figure 5
<p>CDK5 level altered cell toxicity induced by mHTT. The effect of CDK5 overexpression or knocking down was evaluated in mouse striatal cells with different poly Q (SThdh <sup>Q7/Q7</sup> or SThdh <sup>Q111/Q111</sup>). Cells were transfected with either a plasmid expressing human CDK5 or pooled siRNA targeting mouse CDK5 for 24 h. Cell death was measured with CytoTox-Glo cytotoxicity assay kit (Promega). The experiment was repeated by at least two different analysts. Each experiment had n = 3. One representative experiment is presented. Two-way ANOVA with Tukey’s multiple comparation was used for analysis. * <span class="html-italic">p</span> &lt; 0.05; ** <span class="html-italic">p</span> &lt; 0.01; *** <span class="html-italic">p</span> &lt; 0.001.</p>
Full article ">Figure 6
<p>Phospho-null modification of S1181 and S1201 of mHTT altered the mHTT-induced cell toxicity. S1181 and S1201 in the plasmid of FL-82Q were artificially modified to alanine (A). (<b>A</b>) Modified plasmids were transiently transfected into HEK293 cells for 72 h, and cell toxicity was measured by caspase3/7 activity. (<b>B</b>) The modified plasmids were transient transfected in primary cortical neurons, and cell death was analyzed by nuclei condensation assay. The experiment was repeated by at least two different analysts. Each experiment had n = 3. One representative experiment is presented. One-way ANOVA with Dunnett’s multiple comparation was used for analysis. * <span class="html-italic">p</span> &lt; 0.05; ** <span class="html-italic">p</span> &lt; 0.01; *** <span class="html-italic">p</span> &lt; 0.001.</p>
Full article ">Figure 7
<p>Roscovitine protected cells from mHTT-induced toxicity. Roscovitine was used in different HD cell models to evaluate its effect on mHTT-induced toxicity. (<b>A</b>). The effect of roscovitine on mHTT-induced toxicity in SThdh cells expressing Q111 cells. SThdh <sup>Q111/Q111</sup> cells were treated with roscovitine for 24 h under serum withdrawal conditions, and cell toxicity was measured using a CytoTox kit. (<b>B</b>). The effect of roscovitine on mHTT-induced toxicity in primary cortical neuronal HD cell model. Primary cultured cortical neurons were transiently transfected with plasmids expressing either normal Q (23Q) or poly Q (82Q) for 4 h and then treated with or without roscovitine for 48 h. A nuclei condensation assay was used to evaluate cell death. The experiment was repeated by at least two different analysts. Each experiment had <span class="html-italic">n</span> = 3. One representative experiment is presented. W/O = serum withdrawal. One-way ANOVA with Dunnett’s multiple comparation was used for analysis. * <span class="html-italic">p</span> &lt; 0.05; ** <span class="html-italic">p</span> &lt; 0.01.</p>
Full article ">Figure 8
<p>Roscovitine reduced the phosphorylation of S1181 and S1201 of mHTT. Roscovitine reduced p-S1181-HTT and p-S1201-HTT in vitro by inhibiting CDK5 but not CDK1. (<b>A</b>) The representative western blot for p-S1181 in HEK293 cells transfected with a plasmid expressing FL-82Q and treated with or without roscovitine for 48 h. (<b>B</b>) The representative western blot for p-S1201 in HEK293 cells transfected with a plasmid expressing FL-82Q and treated with or without roscovitine for 48 h. (<b>C</b>) The representative western blot for CDK5 in HEK293 cells transfected with a plasmid expressing FL-82Q and treated with or without roscovitine for 48 h. (<b>D</b>) The representative western blot for CDK1 in HEK293 cells transfected with a plasmid expressing FL-82Q and treated with or without roscovitine for 48 h. (<b>E</b>) Quantification of p-S1181 in A. (<b>F</b>) Quantification of p-S1201 in B. (<b>G</b>) Quantification of CDK5 in C. (<b>H</b>) Quantification of CDK1 in D. The experiment was repeated by at least two different analysts. Each experiment had n = 3. One representative experiment is presented. Ros~ = Roscovitine. A two-tailed Student <span class="html-italic">t</span>-test was used. * <span class="html-italic">p</span> &lt; 0.05; ** <span class="html-italic">p</span> &lt; 0.01.</p>
Full article ">Figure 9
<p>Roscovitine penetrated the mouse brain and inhibited CDK5 activity in the zQ175 HD mouse brain. Variant doses of roscovitine were injected into 4-month-old mice through intraperitoneal injection (IP). Plasma and brain samples were collected at different time points after injection. The concentration of roscovitine was measured by LCMS/MS. (<b>A</b>) Brain concentration of roscovitine at different time points after acute IP injection with variant doses. Each group has 4–5 mice. (<b>B</b>) The CDK5 activity in the brain of mice injected with roscovitine for three weeks. Two doses of roscovitine were injected into 4-month-old zQ175HD mice by IP daily for three weeks. Twenty-four hours after the last injection, the mouse brain samples were collected, and the CDK5 activity was measured using a commercial kit from Promega. Animal number is indicated in the bar graph for each group. R-25 = 25 mg/kg of roscovitine. R-50 = 50 mg/kg of roscovitine. One-way ANOVA with Fish’s LSD was used for analysis. * <span class="html-italic">p</span> &lt; 0.05; ** <span class="html-italic">p</span> &lt; 0.01.</p>
Full article ">Figure 10
<p>Tolerability of mice injected with roscovitine by IP administration. (<b>A</b>) The body weight loss of zQ175 HD mice injected with roscovitine. (<b>B</b>) The stride length (by CatWalk) in zQ175 HD mice before and after being injected with roscovitine. Roscovitine was injected by IP daily for three weeks. Animal number for each group is indicated in the bar graphs. V = Vehicle, R = roscovitine. R-25 = 25 mg/kg of roscovitine. R-50 = 50 mg/kg of roscovitine. One-way ANOVA with Fish’s LSD was used for analysis.</p>
Full article ">Figure 11
<p>Molecular neurobiological measurement in the brain of zQ175 HD mice injected with roscovitine by IP. Brain samples were collected as previously described. The cortex was dissected, and lysates were made for western blot analysis. (<b>A</b>) The expression of a pan-neuronal marker, NeuN. (<b>B</b>) The expression of astrocyte marker GFAP. (<b>C</b>) The expression of microglial marker IBA1. (<b>D</b>) The expression of mHTT marker MW1. (<b>E</b>) The quantification of NeuN. (<b>F</b>) The quantification of GFAP. (<b>G</b>) The quantification of IBA1. (<b>H</b>) The quantification of MW1. Animal number is indicated in the bar graph for each group. Veh~ = Vehicle, R25 = 25 mg/kg of roscovitine. R50 = 50 mg/kg of roscovitine. One-way ANOVA with Fish’s LSD was used for analysis.</p>
Full article ">
21 pages, 5193 KiB  
Article
Proteomic Profiling of Venoms from Bungarus suzhenae and B. bungaroides: Enzymatic Activities and Toxicity Assessment
by Chenying Yang, Li Ding, Qiyi He, Xiya Chen, Haiting Zhu, Feng Chen, Wanzhou Yang, Yuexin Pan, Zhiyuan Tai, Wenhao Zhang, Zeyuan Yu, Zening Chen and Xiaodong Yu
Toxins 2024, 16(11), 494; https://doi.org/10.3390/toxins16110494 (registering DOI) - 16 Nov 2024
Abstract
Kraits are venomous snakes of the genus Bungarus from the family Elapidae. Their venom typically demonstrates neurotoxicity; however, the toxicity is significantly influenced by the snake’s species and geographical origin. Among the Bungarus species, Bungarus suzhenae and B. bungaroides have been poorly [...] Read more.
Kraits are venomous snakes of the genus Bungarus from the family Elapidae. Their venom typically demonstrates neurotoxicity; however, the toxicity is significantly influenced by the snake’s species and geographical origin. Among the Bungarus species, Bungarus suzhenae and B. bungaroides have been poorly studied, with little to no information available regarding their venom composition. In this study, a proteomic approach was employed using LC-MS/MS to identify proteins from trypsin-digested peptides. The analysis revealed 102 venom-related proteins from 18 distinct functional protein families in the venom of B. suzhenae, with the primary components being three-finger toxins (3-FTx, 25.84%), phospholipase A2 (PLA2, 40.29%), L-amino acid oxidase (LAAO, 10.33%), Kunitz-type serine protease inhibitors (KUN, 9.48%), and snake venom metalloproteinases (SVMPs, 6.13%). In the venom of B. bungaroides, 99 proteins from 17 families were identified, with primary components being 3-FTx (33.87%), PLA2 (37.91%), LAAO (4.21%), and KUN (16.60%). Enzymatic activity assays confirmed the presence of key venom enzymes. Additionally, the LD50 values for B. suzhenae and B. bungaroides were 0.0133 μg/g and 0.752 μg/g, respectively, providing a reference for toxicity studies of these two species. This research elucidates the proteomic differences in the venoms of these two species, offering a foundation for developing antivenoms and clinical treatments for envenomation. Full article
(This article belongs to the Special Issue Transcriptomic and Proteomic Study on Animal Venom: Looking Forward)
Show Figures

Figure 1

Figure 1
<p>Distribution ranges of <span class="html-italic">B. suzhenae</span> and <span class="html-italic">B. bungaroides</span>. The brown area represents the distribution of <span class="html-italic">B. suzhenae</span>, which is primarily found in Yingjiang County, Dehong Prefecture, Yunnan Province, China, and Kachin State, Myanmar. The yellow area indicates the distribution of <span class="html-italic">B. bungaroides</span>, which is mainly located in Sikkim and Meghalaya in India, Nujiang Lisu Autonomous Prefecture, Yunnan Province, and Medog County in Tibet, China. Blue star and green triangle on the map denote sampling points for <span class="html-italic">B. suzhenae</span> and <span class="html-italic">B. bungaroides</span>, respectively.</p>
Full article ">Figure 2
<p>Relative abundance of toxin protein families in the venoms of <span class="html-italic">B. suzhenae</span> and <span class="html-italic">B. bungaroides</span> as determined by LC-MS/MS. (<b>A</b>) Shows the relative abundance of various protein families in <span class="html-italic">B. suzhenae</span> venom; (<b>B</b>) shows the same for <span class="html-italic">B. bungaroides</span> venom. Abbreviations include 3-FTx (three-finger toxin), PLA<sub>2</sub> (phospholipase A<sub>2</sub>), PLB (phospholipase B), CRISP (cysteine-rich secretory protein), SVMP (snake venom metalloproteinase), SVSP (snake venom serine protease), LAAO (L-amino acid oxidase), CTL (C-type lectin), KUN (Kunitz-type serine protease inhibitor), NP (natriuretic peptide), CYS (cystatin), NGF (nerve growth factor), AChE (acetylcholinesterase), PI (PLA<sub>2</sub> inhibitor), PDE (phosphodiesterase), 5′-NT (5′-nucleotidase), VESP (vespryn), and HAase (hyaluronidase).</p>
Full article ">Figure 3
<p>Comparison of the content of 3-FTx protein subfamilies in the venoms of nine Bungarus species. * the ones studied in this research: <span class="html-italic">B. suzhenae</span> and <span class="html-italic">B. bungaroides</span>. Other species include <span class="html-italic">B. multicinctus-a</span> (Guangdong, China) [<a href="#B24-toxins-16-00494" class="html-bibr">24</a>], <span class="html-italic">B. multicinctus-b</span> (Taiwan, China) [<a href="#B24-toxins-16-00494" class="html-bibr">24</a>], <span class="html-italic">B. multicinctus-c</span> (Guangxi, China) [<a href="#B25-toxins-16-00494" class="html-bibr">25</a>], <span class="html-italic">B. multicinctus-d</span> (Vietnam) [<a href="#B26-toxins-16-00494" class="html-bibr">26</a>], <span class="html-italic">B. caeruleus</span> (India) [<a href="#B27-toxins-16-00494" class="html-bibr">27</a>], <span class="html-italic">B. sindanus</span> (Pakistan) [<a href="#B28-toxins-16-00494" class="html-bibr">28</a>], and <span class="html-italic">B. flaviceps</span> (Malaysia) [<a href="#B29-toxins-16-00494" class="html-bibr">29</a>]. Subfamilies include LNX (long neurotoxin), SNX (short neurotoxin), WNX (weak neurotoxin), and MTLP (Muscarinic toxin-like proteins).</p>
Full article ">Figure 4
<p>Comparison of the content of PLA<sub>2</sub> protein subfamilies in the venoms of nine Bungarus species. * the ones studied in this research: <span class="html-italic">B. suzhenae</span> and <span class="html-italic">B. bungaroides</span>. Other species include <span class="html-italic">B. multicinctus-a</span> (Guangdong, China) [<a href="#B24-toxins-16-00494" class="html-bibr">24</a>], <span class="html-italic">B. multicinctus-b</span> (Taiwan, China) [<a href="#B24-toxins-16-00494" class="html-bibr">24</a>], <span class="html-italic">B. multicinctus-c</span> (Guangxi, China) [<a href="#B25-toxins-16-00494" class="html-bibr">25</a>], <span class="html-italic">B. multicinctus-d</span> (Vietnam) [<a href="#B26-toxins-16-00494" class="html-bibr">26</a>], <span class="html-italic">B. sindanus</span> (Pakistan) [<a href="#B28-toxins-16-00494" class="html-bibr">28</a>], <span class="html-italic">B. fasciatus-a</span> (Vietnam) [<a href="#B26-toxins-16-00494" class="html-bibr">26</a>], and <span class="html-italic">B. flaviceps</span> (Malaysia) [<a href="#B29-toxins-16-00494" class="html-bibr">29</a>]. Subfamilies include β-BGT (beta-bungarotoxin), Acidic PLA<sub>2</sub> (acidic phospholipase A<sub>2</sub>), and Basic PLA<sub>2</sub> (basic phospholipase A<sub>2</sub>).</p>
Full article ">Figure 5
<p>Comparison of minor toxin-related protein families in the venoms of various Bungarus species. Abbreviations include Kunitz-type serine protease inhibitors (KUNs), L-amino acid oxidase (LAAO), snake venom metalloproteinases (SVMPs) and acetylcholinesterase (AChE). * the ones studied in this research: <span class="html-italic">B. suzhenae</span> and <span class="html-italic">B. bungaroides</span>. Other species include <span class="html-italic">B. multicinctus-a</span> (Guangdong, China) [<a href="#B24-toxins-16-00494" class="html-bibr">24</a>], <span class="html-italic">B. multicinctus-b</span> (Taiwan, China) [<a href="#B24-toxins-16-00494" class="html-bibr">24</a>], <span class="html-italic">B. multicinctus-c</span> (Guangxi, China) [<a href="#B25-toxins-16-00494" class="html-bibr">25</a>], <span class="html-italic">B. multicinctus-d</span> (Vietnam) [<a href="#B26-toxins-16-00494" class="html-bibr">26</a>], <span class="html-italic">B. candidus</span> (Malaysia) [<a href="#B9-toxins-16-00494" class="html-bibr">9</a>], <span class="html-italic">B. caeruleus</span> (India) [<a href="#B27-toxins-16-00494" class="html-bibr">27</a>], <span class="html-italic">B. sindanus</span> (Pakistan) [<a href="#B28-toxins-16-00494" class="html-bibr">28</a>], <span class="html-italic">B. fasciatus-a</span> (Vietnam) [<a href="#B26-toxins-16-00494" class="html-bibr">26</a>], <span class="html-italic">B. fasciatus-b</span> (Malaysia) [<a href="#B9-toxins-16-00494" class="html-bibr">9</a>], and <span class="html-italic">B. flaviceps</span> (Malaysia) [<a href="#B29-toxins-16-00494" class="html-bibr">29</a>].</p>
Full article ">Figure 6
<p>Biochemical activities of venoms from <span class="html-italic">B. suzhenae</span> and <span class="html-italic">B. bungaroides</span>. This figure depicts the (<b>A</b>) PLA<sub>2</sub>, (<b>B</b>) LAAO, (<b>C</b>) SVMP, and (<b>D</b>) Fibrinogen-degrading activities of the venoms. Panel (<b>D</b>) shows the fibrinogen electrophoresis patterns: Lane Fib represents untreated fibrinogen, Lane a and b show fibrinogen hydrolysis by <span class="html-italic">B. suzhenae</span> venom and by <span class="html-italic">B. suzhenae</span> venom with EDTA as an inhibitor, respectively, while Lane c and d show the same for <span class="html-italic">B. bungaroides</span> venom. All experiments were performed in triplicate, with error bars representing standard deviation. Statistical significance was assessed with multiple comparison tests: <span class="html-italic">p</span> &gt; 0.05 (ns), <span class="html-italic">p</span> &lt; 0.0002 (***), <span class="html-italic">p</span> &lt; 0.0001 (****).</p>
Full article ">Figure 7
<p>Hemolytic activities of venoms from <span class="html-italic">B. suzhenae</span> and <span class="html-italic">B. bungaroides</span>. (<b>A</b>) Illustrates the direct hemolytic activity of PLA2 on red blood cells, expressed as a percentage in relation to the positive control (1% Triton X). (<b>B</b>) Shows the hemolytic effect of phospholipids generated by PLA<sub>2</sub> hydrolysis on red blood cells. All tests were carried out in triplicate, with error bars denoting standard deviation. Statistical significance was assessed with multiple comparison tests: <span class="html-italic">p</span> &lt; 0.05 (*), <span class="html-italic">p</span> &lt; 0.002 (**), <span class="html-italic">p</span> &lt; 0.0001 (****).</p>
Full article ">
31 pages, 4228 KiB  
Article
Environmental Impact of Wind Farms
by Mladen Bošnjaković, Filip Hrkać, Marija Stoić and Ivan Hradovi
Environments 2024, 11(11), 257; https://doi.org/10.3390/environments11110257 (registering DOI) - 16 Nov 2024
Abstract
The aim of this article is to analyse the global environmental impact of wind farms, i.e., the effects on human health and the local ecosystem. Compared to conventional energy sources, wind turbines emit significantly fewer greenhouse gases, which helps to mitigate global warming. [...] Read more.
The aim of this article is to analyse the global environmental impact of wind farms, i.e., the effects on human health and the local ecosystem. Compared to conventional energy sources, wind turbines emit significantly fewer greenhouse gases, which helps to mitigate global warming. During the life cycle of a wind farm, 86% of CO2 emissions are generated by the extraction of raw materials and the manufacture of wind turbine components. The water consumption of wind farms is extremely low. In the operational phase, it is 4 L/MWh, and in the life cycle, one water footprint is only 670 L/MWh. However, wind farms occupy a relatively large total area of 0.345 ± 0.224 km2/MW of installed capacity on average. For this reason, wind farms will occupy more than 10% of the land area in some EU countries by 2030. The impact of wind farms on human health is mainly reflected in noise and shadow flicker, which can cause insomnia, headaches and various other problems. Ice flying off the rotor blades is not mentioned as a problem. On a positive note, the use of wind turbines instead of conventionally operated power plants helps to reduce the emission of particulate matter 2.5 microns or less in diameter (PM 2.5), which are a major problem for human health. In addition, the non-carcinogenic toxicity potential of wind turbines for humans over the entire life cycle is one of the lowest for energy plants. Wind farms can have a relatively large impact on the ecological system and biodiversity. The destruction of animal migration routes and habitats, the death of birds and bats in collisions with wind farms and the negative effects of wind farm noise on wildlife are examples of these impacts. The installation of a wind turbine at sea generates a lot of noise, which can have a significant impact on some marine animals. For this reason, planners should include noise mitigation measures when selecting the site for the future wind farm. The end of a wind turbine’s service life is not a major environmental issue. Most components of a wind turbine can be easily recycled and the biggest challenge is the rotor blades due to the composite materials used. Full article
(This article belongs to the Collection Trends and Innovations in Environmental Impact Assessment)
20 pages, 1015 KiB  
Review
Recent Advances in Omics, Computational Models, and Advanced Screening Methods for Drug Safety and Efficacy
by Ahrum Son, Jongham Park, Woojin Kim, Yoonki Yoon, Sangwoon Lee, Jaeho Ji and Hyunsoo Kim
Toxics 2024, 12(11), 822; https://doi.org/10.3390/toxics12110822 (registering DOI) - 16 Nov 2024
Abstract
It is imperative to comprehend the mechanisms that underlie drug toxicity in order to enhance the efficacy and safety of novel therapeutic agents. The capacity to identify molecular pathways that contribute to drug-induced toxicity has been significantly enhanced by recent developments in omics [...] Read more.
It is imperative to comprehend the mechanisms that underlie drug toxicity in order to enhance the efficacy and safety of novel therapeutic agents. The capacity to identify molecular pathways that contribute to drug-induced toxicity has been significantly enhanced by recent developments in omics technologies, such as transcriptomics, proteomics, and metabolomics. This has enabled the early identification of potential adverse effects. These insights are further enhanced by computational tools, including quantitative structure–activity relationship (QSAR) analyses and machine learning models, which accurately predict toxicity endpoints. Additionally, technologies such as physiologically based pharmacokinetic (PBPK) modeling and micro-physiological systems (MPS) provide more precise preclinical-to-clinical translation, thereby improving drug safety assessments. This review emphasizes the synergy between sophisticated screening technologies, in silico modeling, and omics data, emphasizing their roles in reducing late-stage drug development failures. Challenges persist in the integration of a variety of data types and the interpretation of intricate biological interactions, despite the progress that has been made. The development of standardized methodologies that further enhance predictive toxicology is contingent upon the ongoing collaboration between researchers, clinicians, and regulatory bodies. This collaboration ensures the development of therapeutic pharmaceuticals that are more effective and safer. Full article
(This article belongs to the Special Issue Advances in Computational Toxicology and Their Exposure)
17 pages, 740 KiB  
Article
A Phase II, Open-Label Study of Lenalidomide and Dexamethasone Followed by Donor Lymphocyte Infusions in Relapsed Multiple Myeloma Following Upfront Allogeneic Stem Cell Transplant
by Richard LeBlanc, Stéphanie Thiant, Rafik Terra, Imran Ahmad, Jean-Sébastien Claveau, Nadia Bambace, Léa Bernard, Sandra Cohen, Jean-Sébastien Delisle, Silvy Lachance, Thomas Kiss, Denis-Claude Roy, Guy Sauvageau and Jean Roy
Curr. Oncol. 2024, 31(11), 7258-7274; https://doi.org/10.3390/curroncol31110535 (registering DOI) - 16 Nov 2024
Viewed by 1
Abstract
Background: To date, the only potential curative treatment for multiple myeloma (MM) remains allogeneic (allo) hematopoietic cell transplant (HCT), although, most patients will eventually relapse. In relapsed patients, donor lymphocyte infusions (DLIs) have been reported to control disease, but the optimal strategy prior [...] Read more.
Background: To date, the only potential curative treatment for multiple myeloma (MM) remains allogeneic (allo) hematopoietic cell transplant (HCT), although, most patients will eventually relapse. In relapsed patients, donor lymphocyte infusions (DLIs) have been reported to control disease, but the optimal strategy prior to and doses of DLIs remain unclear. With this study (NCT03413800), we aimed to investigate the efficacy and toxicity of lenalidomide and dexamethasome (Len/Dex) followed by escalating pre-determined doses of DLIs in MM patients who relapsed after allo HCT. Methods: Patients aged 18–65 years with relapsed MM following upfront tandem autologous (auto)/allo HCT were eligible. Treatment consisted of six cycles of Len/Dex followed by three standardized doses of DLIs: 5 × 106 CD3+/kg, 1 × 107/kg and 5 × 107/kg every 6 weeks. Bone marrow minimal measurable disease (MRD) using flow cytometry (10−5) was performed at enrolment, then every 3 months for 2 years or until disease progression, in a subset of patients. The primary endpoint was efficacy as measured by progression-free survival (PFS) at 2 years following Len/Dex/DLIs. Secondary objectives were safety including GVHD, response including MRD status and overall survival (OS). Results: A total of 22 patients participated in this study, including 62% with high-risk cytogenetics. With a median follow-up of 5.3 years (range: 4.1–6.1), PFS and OS were 26.5% (95% CI: 10.4–45.9%) and 69.2% (95% CI: 43.3–85.1%), respectively. Overall, the best responses achieved post-Len/Dex + DLIs were complete remission in 9.1%, very good partial response in 50%, and progressive disease in 40.9%. Among the nine patients tested for MRD, only two achieved a negative status after receiving DLIs. Six patients died, all due to disease progression. No acute GVHD was observed after DLIs. We report a very low incidence of moderate/severe chronic GVHD of 18.2% with no need for systemic immunosuppressants one year after diagnosis. No unexpected adverse events were observed. Interestingly, a positive correlation between response to Len/Dex re-induction and response to DLIs was found (p = 0.0032). Conclusions: Our findings suggest that Len/Dex/DLIs in second line treatment after upfront tandem auto/allo HCT in relapsed MM patients remains feasible and safe. With a potential correlation between induction chemotherapy and DLI responses, more potent induction regimens together with higher doses of DLIs should be considered in the future. Full article
(This article belongs to the Section Cell Therapy)
Show Figures

Figure 1

Figure 1
<p>Overall schedule of treatments and measurable residual disease (MRD) assessments.</p>
Full article ">Figure 2
<p>Kaplan–Meier estimates of (<b>A</b>) progression-free survival and (<b>B</b>) overall survival after initiation of first cycle of lenalidomide.</p>
Full article ">
21 pages, 1980 KiB  
Article
Influence of Organic Matter and Speciation on the Dynamics of Trace Metal Adsorption on Microplastics in Marine Conditions
by Ana Rapljenović, Marko Viskić, Stanislav Frančišković-Bilinski and Vlado Cuculić
Toxics 2024, 12(11), 820; https://doi.org/10.3390/toxics12110820 (registering DOI) - 16 Nov 2024
Viewed by 36
Abstract
Dissolved organic matter (DOM), primarily in the form of humic acid (HA), plays a crucial role in trace metal (TM) speciation and their subsequent adsorption dynamics on microplastics (MP) in aquatic environments. This study evaluates the impact of environmentally relevant concentrations of HA [...] Read more.
Dissolved organic matter (DOM), primarily in the form of humic acid (HA), plays a crucial role in trace metal (TM) speciation and their subsequent adsorption dynamics on microplastics (MP) in aquatic environments. This study evaluates the impact of environmentally relevant concentrations of HA on the adsorption behaviors of essential (Co, Cu, Ni, and Zn) and toxic (Cd and Pb) TMs onto polyethylene (PE) and polypropylene (PP) pellets, as well as PP fibers under marine conditions, during a six-week experiment. The HA concentrations were 0.1, 1, and 5 mg/L, while all metals were in the same amounts (10 µg/L). Results reveal that HA significantly influences the adsorption of Cu, Pb, and Zn on MP, particularly on PP fibers, which exhibited the greatest TM adsorption dynamics. The adsorption patterns correspond to the concentrations of these metals in seawater, with the sequence for pellets being Zn > Cu > Pb > Ni > Co~Cd, and for fibers Cu > Zn > Pb > Co~Ni > Cd. Speciation modeling supported these findings, indicating that Cu, Pb, and Zn predominantly associate with HA in seawater, facilitating their adsorption on MP, whereas Cd, Co, and Ni mainly form free ions and inorganic complexes, resulting in slower adsorption dynamics. Statistical analysis confirmed the influence of HA on the adsorption of Cd, Pb, Cu, and Ni. By investigating the dynamics of TM adsorption on plastics, the influence of DOM on these two contaminants under marine conditions was evaluated. The presented results can help in forming a better understanding of synergistic plastic and trace metal pollution in marine systems that are relevant at the global level, since both contaminants pose a serious threat to aquatic ecosystems. Full article
(This article belongs to the Section Ecotoxicology)
26 pages, 3497 KiB  
Article
Developing Innovative Apolar Gels Based on Cellulose Derivatives for Cleaning Metal Artworks
by Andrea Macchia, Camilla Zaratti, Davide Ciogli, Giovanni Rivici, Silvia Pilati, Nereo Sbiri, Tilde de Caro and Maria Assunta Navarra
Gels 2024, 10(11), 747; https://doi.org/10.3390/gels10110747 (registering DOI) - 16 Nov 2024
Viewed by 58
Abstract
Abstract: The use of organic solvents, particularly those of a non-polar nature, is a common practice during cleaning operations in the restoration of polychrome artworks and metallic artifacts. However, these solvents pose significant risks to the health of operators and the environment. This [...] Read more.
Abstract: The use of organic solvents, particularly those of a non-polar nature, is a common practice during cleaning operations in the restoration of polychrome artworks and metallic artifacts. However, these solvents pose significant risks to the health of operators and the environment. This study explores the formulation of innovative gels based on non-polar solvents and cellulose derivatives, proposing a safe and effective method for cleaning metallic artworks. The study is focused on a toxic apolar solvent, Ligroin, identified as one of the most widely used solvents in the cultural heritage treatments, and some “green” alternatives such as Methyl Myristate and Isopropyl Palmitate. The main challenge lies in overcoming the chemical incompatibility between non-polar solvents and polar thickening agents like cellulose ethers. To address this problem, the research was based on a hydrophilic–lipophilic balance (HLB) system and Hansen solubility parameters (HSPs) to select appropriate surfactants, ensuring the stability and effectiveness of the formulated gels. Stability, viscosity, and solvent release capacity of gels were analyzed using Static Light Multiple Scattering (Turbiscan), viscometry, and thermogravimetric analysis (TGA). The efficacy of cleaning in comparison with Ligroin liquid was evaluated on a metal specimen treated with various apolar protective coatings used commonly in the restoration of metallic artifacts, such as microcrystalline waxes (Reswax, Soter), acrylic resins (Paraloid B44), and protective varnishes (Incral, Regalrez). Multispectral analysis, digital optical microscopy, FTIR spectroscopy, and spectrocolorimetry allowed for the assessment of the gels’ ability to remove the different protective coatings, the degree of cleaning achieved, and the presence of any residues. The results obtained highlight the ability of the formulated gels to effectively remove protective coatings from metallic artifacts. Cetyl Alcohol proved to be the most versatile surfactant to realize a stable and efficient gel. The gels based on Methyl Myristate and Isopropyl Palmitate showed promising results as “green” alternatives to Ligroin, although in some cases, they exhibited less selectivity in the removal of protective coatings. Full article
(This article belongs to the Special Issue Design of Supramolecular Hydrogels)
21 pages, 1249 KiB  
Article
Physiological Response of Lettuce (Lactuca sativa L.) Grown on Technosols Designed for Soil Remediation
by Mateo González-Quero, Antonio Aguilar-Garrido, Mario Paniagua-López, Carmen García-Huertas, Manuel Sierra-Aragón and Begoña Blasco
Plants 2024, 13(22), 3222; https://doi.org/10.3390/plants13223222 (registering DOI) - 16 Nov 2024
Viewed by 74
Abstract
This study focuses on the physiological response of lettuce grown on Technosols designed for the remediation of soils polluted by potentially harmful elements (PHEs: As, Cd, Cu, Fe, Pb, and Zn). Lettuce plants were grown in five treatments: recovered (RS) and polluted soil [...] Read more.
This study focuses on the physiological response of lettuce grown on Technosols designed for the remediation of soils polluted by potentially harmful elements (PHEs: As, Cd, Cu, Fe, Pb, and Zn). Lettuce plants were grown in five treatments: recovered (RS) and polluted soil (PS) as controls, and three Technosols (TO, TS, and TV) consisting of 60% PS mixed with 2% iron sludge, 20% marble sludge, and 18% organic wastes (TO: composted olive waste, TS: composted sewage sludge, and TV: vermicompost of garden waste). The main soil properties and PHE solubility were measured, together with physiological parameters related to phytotoxicity in lettuce such as growth, photosynthetic capacity, oxidative stress, and antioxidant defence. All Technosols improved unfavourable conditions of PS (i.e., neutralised acidity and enhanced OC content), leading to a significant decrease in Cd, Cu, and Zn mobility. Nevertheless, TV was the most effective as the reduction in PHEs mobility was higher. Furthermore, lettuce grown on TV and TO showed higher growth (+90% and +41%) than PS, while no increase in TS. However, lower oxidative stress and impact on photosynthetic rate occurred in all Technosols compared to PS (+344% TV, +157% TO, and +194% TS). This physiological response of lettuce proves that PHE phytotoxicity is reduced by Technosols. Thus, this ecotechnology constitutes a potential solution for soil remediation, with effectiveness of Technosols depending largely on its components. Full article
(This article belongs to the Special Issue Potential Hazardous Elements Accumulation in Plants)
21 pages, 1653 KiB  
Review
The Potential of Natural Compounds in UV Protection Products
by Jovana Milutinov, Nebojša Pavlović, Dejan Ćirin, Milica Atanacković Krstonošić and Veljko Krstonošić
Molecules 2024, 29(22), 5409; https://doi.org/10.3390/molecules29225409 (registering DOI) - 16 Nov 2024
Viewed by 154
Abstract
Overexposure to ultraviolet radiation mainly leads to skin disorders (erythema, burns, immunosuppression), skin aging, and skin cancer as the most serious side effect. It has been widely accepted that using sunscreen products is an important way to protect against the harmful effects of [...] Read more.
Overexposure to ultraviolet radiation mainly leads to skin disorders (erythema, burns, immunosuppression), skin aging, and skin cancer as the most serious side effect. It has been widely accepted that using sunscreen products is an important way to protect against the harmful effects of UV rays. Although commercial sunscreens have constantly changed and improved over time, there are emerging concerns about the safety of conventional, organic, UV filters due to adverse effects on humans (such as photoallergic dermatitis, contact sensitivity, endocrine-disrupting effects, etc.) as well as accumulation in the environment and aquatic organisms. This is why natural compounds are increasingly being investigated and used in cosmetic and pharmaceutical sunscreens. Some of these compounds are widely available, non-toxic, safer for use, and have considerable UV protective properties and less side effects. Plant-based compounds such as flavonoids can absorb UVA and UVB rays and possess antioxidant, anticarcinogenic, and anti-inflammatory effects that contribute to photoprotection. Apart from flavonoids, other natural products such as certain vegetable oils, carotenoids, stilbenes, and ferulic acid also have UV-absorbing properties. Some vitamins might also be beneficial for skin protection due to their antioxidant activity. Therefore, the aim of this research was to gain insight into the potential of natural compounds to replace or reduce the amount of conventional UV filters, based on recent research. Full article
(This article belongs to the Special Issue Multifunctional Natural Ingredients in Skin Protection and Care)
Show Figures

Figure 1

Figure 1
<p>Mechanism of action of physical (inorganic) and chemical (organic) UV filters.</p>
Full article ">Figure 2
<p>Classifications of organic UV filters.</p>
Full article ">Figure 3
<p>Chemical structures of some carotenoids.</p>
Full article ">Figure 4
<p>The chemical structures of some vitamins that contribute to protection against UV radiation.</p>
Full article ">
16 pages, 593 KiB  
Article
Dietary Risk Assessment of Cadmium Exposure Through Commonly Consumed Foodstuffs in Mexico
by Alejandra Cantoral, Sonia Collado-López, Larissa Betanzos-Robledo, Héctor Lamadrid-Figueroa, Betzabeth A. García-Martínez, Camilo Ríos, Araceli Díaz-Ruiz, Rosa María Mariscal-Moreno and Martha María Téllez-Rojo
Foods 2024, 13(22), 3649; https://doi.org/10.3390/foods13223649 (registering DOI) - 16 Nov 2024
Viewed by 95
Abstract
Cadmium (Cd) is a toxic heavy metal widely distributed in foodstuffs. In Mexico, few studies have evaluated Cd content in foods. This study aimed to determine Cd concentrations in foodstuffs that are highly consumed and bought in Mexico City to identify foods exceeding [...] Read more.
Cadmium (Cd) is a toxic heavy metal widely distributed in foodstuffs. In Mexico, few studies have evaluated Cd content in foods. This study aimed to determine Cd concentrations in foodstuffs that are highly consumed and bought in Mexico City to identify foods exceeding the Maximum Level (ML) and to assess the health risks of theoretical Cd intake from a diet following the Mexican Dietary Guidelines. A total of 143 foodstuffs were analyzed by atomic absorption spectrophotometry. Theoretical Cd intake was estimated in portions per week and compared with the Cd Tolerable Weekly Intake (TWI = 2.5 μg/kg per body weight). A total of 68.5% of the foodstuffs had detectable Cd concentrations. Higher concentrations were found in oyster mushrooms (0.575 mg/kg), romaine lettuce (0.335 mg/kg), and cocoa powder (0.289 mg/kg). Food groups with higher mean concentrations were vegetables (0.084 mg/kg) and snacks, sweets, and desserts (0.049 mg/kg). Ancho chili and romaine lettuce exceed the ML. The theoretical Cd intake estimation was 1.80, 2.05, and 3.82 μg/kg per body weight for adults, adolescents, and school-age children, respectively. This theoretical Cd intake represents a health risk only for school children exceeding the TWI by 53.2%. Our study confirms the presence and risk of Cd in Mexican foodstuffs and highlights the importance of monitoring programs. Full article
Show Figures

Figure 1

Figure 1
<p>Contribution per food group to the total theoretical dietary weekly cadmium intake by age group, following the recommendations of the Healthy and Sustainable Guidelines for the Mexican population.</p>
Full article ">
24 pages, 5324 KiB  
Review
Research Progress on the Application of Natural Medicines in Biomaterial Coatings
by Yanchao Wang, Huimin Duan, Zhongna Zhang, Lan Chen and Jingan Li
Materials 2024, 17(22), 5607; https://doi.org/10.3390/ma17225607 (registering DOI) - 16 Nov 2024
Viewed by 140
Abstract
With the continuous progress of biomedical technology, biomaterial coatings play an important role in improving the performance of medical devices and promoting tissue repair and regeneration. The application of natural medicine to biological materials has become a hot topic due to its diverse [...] Read more.
With the continuous progress of biomedical technology, biomaterial coatings play an important role in improving the performance of medical devices and promoting tissue repair and regeneration. The application of natural medicine to biological materials has become a hot topic due to its diverse biological activity, low toxicity, and wide range of sources. This article introduces the definition and classification of natural medicines, lists some common natural medicines, such as curcumin, allicin, chitosan, tea polyphenols, etc., and lists some biological activities of some common natural medicines, such as antibacterial, antioxidant, antitumor, and other properties. According to the different characteristics of natural medicines, physical adsorption, chemical grafting, layer-by-layer self-assembly, sol–gel and other methods are combined with biomaterials, which can be used for orthopedic implants, cardiovascular and cerebrovascular stents, wound dressings, drug delivery systems, etc., to exert their biological activity. For example, improving antibacterial properties, promoting tissue regeneration, and improving biocompatibility promote the development of medical health. Although the development of biomaterials has been greatly expanded, it still faces some major challenges, such as whether the combination between the coating and the substrate is firm, whether the drug load is released sustainably, whether the dynamic balance will be disrupted, and so on; a series of problems affects the application of natural drugs in biomaterial coatings. In view of these problems, this paper summarizes some suggestions by evaluating the literature, such as optimizing the binding method and release system; carrying out more clinical application research; carrying out multidisciplinary cooperation; broadening the application of natural medicine in biomaterial coatings; and developing safer, more effective and multi-functional natural medicine coatings through continuous research and innovation, so as to contribute to the development of the biomedical field. Full article
Show Figures

Figure 1

Figure 1
<p>Some applications of biomaterial coatings: (<b>a</b>) Mg-based alloys have been used in neuroscience as filaments within nerve conduits to accelerate nerve regeneration, the nerve electrode, devices for neural recording and monitoring, and stents for carotid artery stenosis and aneurysm treatment [<a href="#B32-materials-17-05607" class="html-bibr">32</a>]; (<b>b</b>) the incorporation of compounds such as titanium dioxide (TiO<sub>2</sub>), dopamine, fluorine-substituted hydroxyapatite (FHA), tetraethyl orthosilicate (TEOS), and silica nanoparticles (SNs) into the hydrogel structure can improve the biocompatibility, stability, and peripheral inflammation of implants [<a href="#B33-materials-17-05607" class="html-bibr">33</a>]; (<b>c</b>) the prepared hydrogels are used for cardiac, nervous, and bone tissue engineering [<a href="#B34-materials-17-05607" class="html-bibr">34</a>]; (<b>d</b>) catechol chitosan diatom hydrogel (CCDHG) was developed for use in TENG electrodes, and m-type defibrillation sensors were developed based on CCDHG-TENG to evaluate low-frequency motion in patients with Parkinson’s disease [<a href="#B35-materials-17-05607" class="html-bibr">35</a>]; (<b>e</b>) plant-based multi-confectionery gums can be used to produce polymer films for active packaging [<a href="#B36-materials-17-05607" class="html-bibr">36</a>]; (<b>f</b>) an antimicrobial coating can be built on the surface of orthopedic implants [<a href="#B37-materials-17-05607" class="html-bibr">37</a>].</p>
Full article ">Figure 2
<p>A dual-loaded multi-layered RSF coating with curcumin and Zn<sup>2+</sup> on PET grafts, which followed a time-programmed pattern of drugs release, could intervene anti-inflammatory and tissue regeneration in a time-matched way, and ultimately improve graft–host integration [<a href="#B77-materials-17-05607" class="html-bibr">77</a>].</p>
Full article ">Figure 3
<p>C-HA-Cys hydrogel coatings were prepared by an amide reaction using catechol hyaluronic acid (C-HA) and cystine (Cys). The H<sub>2</sub>S-releasing donor allicin is loaded into the hydrogel to form a smart biomimetic coating [<a href="#B95-materials-17-05607" class="html-bibr">95</a>].</p>
Full article ">Figure 4
<p>Polyetheretherketone (PEEK), which can be used for orthopedic implants, is selected to form a spongy three-dimensional structure on the surface through a sulfonation reaction and embedded osthole nanoparticles with osteogenic activity. The silk fibroin–berberine coating with antimicrobial function is loaded on the surface of the material [<a href="#B109-materials-17-05607" class="html-bibr">109</a>]. (<b>a</b>) Composition of the coating; (<b>b</b>) The antibacterial and osteogenic functions of the coating.</p>
Full article ">Figure 5
<p>Biomimetic engineering of an endothelium-like coating through the synergic application of bioactive heparin and nitric oxide-generating species. The endothelium–biomimetic coating imparts the modified cardiovascular stent with the ability to combine the physiological capabilities of both heparin and NO, which creates a favorable microenvironment for inhibiting the key components in the coagulation cascade, such as Factor Xa and thrombin (Factor IIa) and platelets, as well as the growth of ECs over SMCs. These features endow the vascular stent with the abilities to impressively improve the antithrombogenicity, induce re-endothelialization, and prevent restenosis in vivo [<a href="#B129-materials-17-05607" class="html-bibr">129</a>].</p>
Full article ">Figure 6
<p>The mechanisms of antibacterial action of propolis—(A) propolis causes damage to the cell membrane, leading the cell contents to leak out, causing cell lysis. (B) Propolis inhibits adenosine triphosphate (ATP) formation, inhibiting mobility and the metabolism of the cell, impeding cell function (C) Propolis inhibits topoisomerase activity, causing DNA damage and mitotic failure [<a href="#B131-materials-17-05607" class="html-bibr">131</a>].</p>
Full article ">Figure 7
<p>Hierarchically hybrid biocoatings on Ti implants are developed by gradual incorporation of polydopamine (PDA), ZnO nanoparticles (nZnO), and chitosan (CS)/nanocrystal hydroxyapatite (nHA) via oxidative self-polymerization, nanoparticle deposition, solvent casting and evaporation methods for enhancing their antibacterial activity and osteogenesis [<a href="#B146-materials-17-05607" class="html-bibr">146</a>].</p>
Full article ">
23 pages, 6586 KiB  
Article
Studies Regarding Antimicrobial Properties of Some Microbial Polyketides Derived from Monascus Strains
by Daniela Albisoru, Nicoleta Radu, Lucia Camelia Pirvu, Amalia Stefaniu, Narcisa Băbeanu, Rusandica Stoica and Dragos Paul Mihai
Antibiotics 2024, 13(11), 1092; https://doi.org/10.3390/antibiotics13111092 (registering DOI) - 16 Nov 2024
Viewed by 180
Abstract
Finding new molecules to prevent the growth of antimicrobial resistance is a hot topic for scientists worldwide. It has been reported that some raw bioproducts containing Monascus polyketides have antimicrobial activities, but extensive studies on this effect have not been conducted. In this [...] Read more.
Finding new molecules to prevent the growth of antimicrobial resistance is a hot topic for scientists worldwide. It has been reported that some raw bioproducts containing Monascus polyketides have antimicrobial activities, but extensive studies on this effect have not been conducted. In this context, our studies aimed to evaluate the antimicrobial properties of six raw bioproducts containing three classes of microbial polyketides biosynthesized by three Monascus strains through solid-state biosynthesis. As a methodology, we performed in silico predictions using programs such as PyMOL v3.0.4 and employed ESI-MS techniques to provide evidence of the presence of the six studied compounds in our bioproducts. The results obtained in silico were validated through in vitro studies using the Kirby-Bauer diffusion method on bacteria and fungi. The test performed in silico showed that Monascorubramine has the highest affinity for both Gram-positive and Gram-negative bacteria, followed by yellow polyketides such as Ankaflavin and Monascin. The estimated pharmacokinetic parameters indicated high gastrointestinal absorption and the potential to cross the blood-brain barrier for all studied compounds. However, the compounds also inhibit most enzymes involved in drug metabolism, presenting some level of toxicity. The best in vitro results were obtained for S. aureus, with an extract containing yellow Monascus polyketides. Predictions made for E. coli were validated in vitro for P. aeruginosa, S. enterica, and S. marcescens, as well as for fungi. Significant antibacterial properties were observed during this study for C. albicans, S. aureus, and fungal dermatophytes for crude bioproducts containing Monascus polyketides. In conclusion, the antimicrobial properties of Monascus polyketides were validated both in silico and in vitro. However, due to their potential toxicity, these bioproducts would be safer to use as topical formulations. Full article
Show Figures

Figure 1

Figure 1
<p>Experimental study design.</p>
Full article ">Figure 2
<p>Molecular docking validation—superposition of predicted poses (pink) of co-crystallized inhibitors on initial conformations (green): (<b>a</b>) trimethoprim in saDHFR binding site (PDB ID: 2w9s, RMSD 0.6535 Å); (<b>b</b>) trimethoprim in ecDHFR binding site (PDB ID: 7mym, RMSD 0.3521 Å); (<b>c</b>) UCP11E in caDHFR binding site (PDB ID: 4hoe, RMSD 0.4389 Å); (<b>d</b>) trimethoprim in hDHFR binding site (PDB ID: 2w3a, RMSD 0.9559 Å).</p>
Full article ">Figure 3
<p>Predicted binding poses of Monascorubramine in DHFR active sites. (<b>a</b>) saDHFR; (<b>b</b>) ecDHFR; (<b>c</b>) caDHFR; (<b>d</b>) hDHFR.</p>
Full article ">Figure 4
<p>2D diagrams of predicted molecular interactions between Monascorubramine and active sites of DHFR homologues. (<b>a</b>) saDHFR; (<b>b</b>) ecDHFR; (<b>c</b>) caDHFR; (<b>d</b>) hDHFR.</p>
Full article ">Figure 5
<p>“Boiled egg” diagram illustrating the distribution of the investigated compounds in the chemical space of molecules that are absorbed in the gastrointestinal (GI) tract or passively permeate the blood–brain barrier (BBB) based on calculated WlogP (octanol/water partition coefficient) and TPSA (topological polar surface area) values. Molecules located in the “egg yolk” are predicted to passively permeate through the BBB. Molecules located in the white area are predicted to be passively absorbed in the GI tract.</p>
Full article ">Figure 6
<p>ESI-MS analysis of a total alcoholic extract of the following: (<b>a</b>) <span class="html-italic">Monascus purpureus</span>; (<b>b</b>) <span class="html-italic">Monascus ruber</span>; (<b>c</b>) <span class="html-italic">Monascus</span> sp. 3 <span class="html-italic">(Monascus ruber</span>; highly productive).</p>
Full article ">Figure 7
<p>Antibacterial properties of polyketides obtained from Monascus-derived bioproducts: (<b>a</b>) antibacterial properties for <span class="html-italic">S. aureus</span> (yellow polyketides exhibit the best activities); (<b>b</b>) antibacterial properties for <span class="html-italic">S. aureus</span> MRSA (yellow polyketides exhibit moderate activities); (<b>c</b>) antibacterial properties for <span class="html-italic">S. marcescens</span> (red polyketides exhibit the best activities); (<b>d</b>) antibacterial properties for <span class="html-italic">P. aeruginosa</span> (red polyketides exhibit moderate antimicrobial activities); (<b>e</b>) antibacterial properties for <span class="html-italic">S. enterica</span> (red polyketides exhibit local-moderate antimicrobial activities).</p>
Full article ">Figure 7 Cont.
<p>Antibacterial properties of polyketides obtained from Monascus-derived bioproducts: (<b>a</b>) antibacterial properties for <span class="html-italic">S. aureus</span> (yellow polyketides exhibit the best activities); (<b>b</b>) antibacterial properties for <span class="html-italic">S. aureus</span> MRSA (yellow polyketides exhibit moderate activities); (<b>c</b>) antibacterial properties for <span class="html-italic">S. marcescens</span> (red polyketides exhibit the best activities); (<b>d</b>) antibacterial properties for <span class="html-italic">P. aeruginosa</span> (red polyketides exhibit moderate antimicrobial activities); (<b>e</b>) antibacterial properties for <span class="html-italic">S. enterica</span> (red polyketides exhibit local-moderate antimicrobial activities).</p>
Full article ">Figure 8
<p>Antifungal properties of polyketides obtained from Monascus-derived bioproducts for the following: (<b>a</b>) <span class="html-italic">Candida albicans</span>; (<b>b</b>) <span class="html-italic">S. brevicaulis</span>, (<b>c</b>) <span class="html-italic">M. gypseum</span>; (<b>d</b>) <span class="html-italic">T. mentagrophytes</span>.</p>
Full article ">Figure 9
<p>Flow diagram used to obtain enhanced extracts of yellow, orange, and red polyketides: (<b>a</b>) Solid-state biosynthesis of <span class="html-italic">Monascus</span> bioproducts (RYR); (<b>b</b>) Sample preparation of <span class="html-italic">Monascus</span> bioproducts for analysis; (<b>c</b>) Obtaining <span class="html-italic">Monascus</span> extract with yellow polyketides; (<b>d</b>) Obtaining <span class="html-italic">Monascus</span> extract with orange polyketides; (<b>e</b>) Obtaining <span class="html-italic">Monascus</span> extract with red polyketides.</p>
Full article ">Figure 9 Cont.
<p>Flow diagram used to obtain enhanced extracts of yellow, orange, and red polyketides: (<b>a</b>) Solid-state biosynthesis of <span class="html-italic">Monascus</span> bioproducts (RYR); (<b>b</b>) Sample preparation of <span class="html-italic">Monascus</span> bioproducts for analysis; (<b>c</b>) Obtaining <span class="html-italic">Monascus</span> extract with yellow polyketides; (<b>d</b>) Obtaining <span class="html-italic">Monascus</span> extract with orange polyketides; (<b>e</b>) Obtaining <span class="html-italic">Monascus</span> extract with red polyketides.</p>
Full article ">
17 pages, 373 KiB  
Review
Genetics, Epigenetics, and the Environment: Are Precision Medicine, Provider Compassion, and Social Justice Effective Public Health Measures to Mitigate Disease Risk and Severity?
by Philip M. Iannaccone, Rebecca J. Ryznar and Lon J. Van Winkle
Int. J. Environ. Res. Public Health 2024, 21(11), 1522; https://doi.org/10.3390/ijerph21111522 (registering DOI) - 16 Nov 2024
Viewed by 203
Abstract
Environmental forces impacting public health include exposure to toxic substances, adverse childhood experiences (ACEs), diet, and exercise. Here, we examine the first two of these forces in some detail since they may be amenable to correction through cultural, medical, and practitioner intervention. At [...] Read more.
Environmental forces impacting public health include exposure to toxic substances, adverse childhood experiences (ACEs), diet, and exercise. Here, we examine the first two of these forces in some detail since they may be amenable to correction through cultural, medical, and practitioner intervention. At the same time, changing people’s dietary and exercise routines are likely more resistant to these interventions and are referred to only incidentally in this review. That is, societal efforts could prevent exposure to toxicants and ACEs—not necessarily requiring cooperation by the affected individuals—whereas changing diet and exercise practices requires an individual’s discipline. Toxic substances considered in this review include endocrine disruptors, arsenics, 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD), the organic solvent, Trichloroethylene (TCE), and the Benzo[a]pyrene (B[a]P) produced from incomplete combustion of tobacco and other organic materials. Exposure to each of these toxic substances may have serious adverse health effects, especially in genetically more susceptible individuals. For example, children of mothers exposed to the endocrine disruptor, Atrazine, have significantly lower birth length, weight, and head circumference. Moreover, male offspring exhibit genital abnormalities, and all of these effects may be transgenerational. However, analyses of interactions among genes, the environment, and epigenetic modifications have already revealed distinctive individual risks of adverse reactions to toxic exposure. So, interventions through precision medicine might improve the health of those exposed individuals. Adults previously exposed to more than one ACE (e.g., child abuse and inter-parental violence) are more likely to develop anxiety, cancer, and diabetes. Detecting ACE exposures in children in the general population is fraught with difficulty. Thus, the risks of ACEs to our health remain even more insidious than exposures to toxicants. Nevertheless, higher provider compassion is associated with significantly better clinical outcomes for patients with these afflictions. For all these reasons, the first major aim of this review is to recount several of the major forces contributing to or impairing public health. Our second major aim is to examine mitigating influences on these forces, including social justice and provider compassion in the setting of precision medicine. Idealistically, these mitigators might eventually lead to the development of more cooperative and compassionate cultures and societies. Full article
22 pages, 2251 KiB  
Article
The Descriptive and Disproportionality Assessment of EudraVigilance Database Reports on Capecitabine Induced Cardiotoxicity
by Razvan Constantin Vonica, Anca Butuca, Andreea Loredana Vonica-Tincu, Claudiu Morgovan, Manuela Pumnea, Remus Calin Cipaian, Razvan Ovidiu Curca, Florina Batar, Vlad Vornicu, Adelaida Solomon, Adina Frum, Carmen Maximiliana Dobrea, Dan Damian Axente and Felicia Gabriela Gligor
Cancers 2024, 16(22), 3847; https://doi.org/10.3390/cancers16223847 (registering DOI) - 16 Nov 2024
Viewed by 132
Abstract
Capecitabine (CAP) is one of the most commonly prescribed fluoropyrimidines in oncology, especially in the treatment of colon cancer. Cardiac toxicity is a severe and potentially lethal adverse drug reaction (ADR) against fluoropyrimidines. Cardiac ADRs, such as myocardial infarction (MI), heart failure (HF), [...] Read more.
Capecitabine (CAP) is one of the most commonly prescribed fluoropyrimidines in oncology, especially in the treatment of colon cancer. Cardiac toxicity is a severe and potentially lethal adverse drug reaction (ADR) against fluoropyrimidines. Cardiac ADRs, such as myocardial infarction (MI), heart failure (HF), arrhythmias, and a number of cardiomyopathies, are reported for these molecules. To have a better understanding of the risk–benefit ratio of colon cancer therapy, a pharmacovigilance study of real-world evidence of the cardiac toxicity of antineoplastic agents is required. Aim: This post-marketing research on CAP aims to assess the risk of cardiac toxicity. Five other antitumor drugs used in colorectal cancer, i.e., 5-fluorouracil (5-FU), irinotecan (IRI), oxaliplatin (OX), bevacizumab (BEV) and panitumumab (PAN), were also studied to create a relative profile of observed cardiotoxicity. Methods: A retrospective study based on reports submitted in the EudraVigilance (EV) database until 28 July 2024 was conducted. Using the aggregated data from EV, a descriptive analysis and disproportionality analysis of cardiac ADRs induced by fluoropyrimidines were performed. To evaluate the disproportionality of the signals, Reporting Odds Ratio (ROR) and 95% confidence interval (95% CI) were calculated by comparison with other drugs used in colorectal cancer: 5-FU, IRI, OX, BEV, and PAN. Results: “Cardiac disorders” represent 3.4% of the total reports for CAP. The value is comparable to 5-FU, but higher than for other drugs. t was observed that there are no significant differences in the occurrence of cardiac ADRs in patients exposed to CAP and 5-FU treatments, and in particular MI and HF. Compared to 5-FU, which could produce cardiac arrythmias with a higher probability than all other drugs, CAP has a higher probability of reporting this ADR only in comparison with IRI (ROR: 1.2971; 95% CI: 1.0196-1.6502). Conclusions: CAP induces adverse cardiovascular reactions, especially MI, HF, and cardiomyopathies. Arrhythmias have been shown to be side effects more frequent associated with 5-FU than with CAP. The results emphasize the need for a rigorous cardiovascular monitoring of patients following treatment with CAP or 5-FU and especially for those with pre-existing cardiac pathology. Full article
Show Figures

Figure 1

Figure 1
<p>The comparative ratio of ADRs reported for each ICSR. 5-FU—5-fluorouracil; BEV—bevacizumab; CAP—capecitabine; IRI—irinotecan; OX—oxaliplatin; PAN—panitumumab.</p>
Full article ">Figure 2
<p>Structure of ADRs by seriousness. 5-FU—5-fluorouracil; BEV—bevacizumab; CAP—capecitabine; IRI—irinotecan; OX—oxaliplatin; PAN—panitumumab.</p>
Full article ">Figure 3
<p>Distribution of ADRs by outcome. ADRs related to (<b>a</b>)—myocardial infarction; (<b>b</b>)—arrhythmias; (<b>c</b>)—heart failure; (<b>d</b>)—cardiomyopathy. 5-FU—5-fluorouracil; BEV—bevacizumab; CAP—capecitabine; IRI—irinotecan; OX—oxaliplatin; PAN—panitumumab; R—recovered; RS—resolved; NR—not recovered; NRS—not resolved; RG—recovering; RSG—resolving; UNKN—unknown.</p>
Full article ">Figure 3 Cont.
<p>Distribution of ADRs by outcome. ADRs related to (<b>a</b>)—myocardial infarction; (<b>b</b>)—arrhythmias; (<b>c</b>)—heart failure; (<b>d</b>)—cardiomyopathy. 5-FU—5-fluorouracil; BEV—bevacizumab; CAP—capecitabine; IRI—irinotecan; OX—oxaliplatin; PAN—panitumumab; R—recovered; RS—resolved; NR—not recovered; NRS—not resolved; RG—recovering; RSG—resolving; UNKN—unknown.</p>
Full article ">Figure 4
<p>ADRs related to main cardiac PTs used for reporting in EV.</p>
Full article ">Figure 5
<p>Disproportionality analysis of ADRs produced by CAP and 5-FU and reported in “Cardiac disorders” SOC. (<b>a</b>)—capecitabine; (<b>b</b>)—5-fluorouracil. 5-FU—5-fluorouracil; BEV—bevacizumab; CAP—capecitabine; IRI—irinotecan; OX—oxaliplatin; PAN—panitumumab. **** <span class="html-italic">p</span> ≤ 0.0001.</p>
Full article ">Figure 5 Cont.
<p>Disproportionality analysis of ADRs produced by CAP and 5-FU and reported in “Cardiac disorders” SOC. (<b>a</b>)—capecitabine; (<b>b</b>)—5-fluorouracil. 5-FU—5-fluorouracil; BEV—bevacizumab; CAP—capecitabine; IRI—irinotecan; OX—oxaliplatin; PAN—panitumumab. **** <span class="html-italic">p</span> ≤ 0.0001.</p>
Full article ">Figure 6
<p>The signals for ADRs related to myocardial infarction produced by capecitabine and 5-fluorouracil. (<b>a</b>)—capecitabine (<b>b</b>)—5-fluorouracil. 5-FU—5-fluorouracil; BEV—bevacizumab; CAP—capecitabine; IRI—irinotecan; OX—oxaliplatin; PAN—panitumumab. ** <span class="html-italic">p</span> ≤ 0.01; **** <span class="html-italic">p</span> ≤ 0.0001.</p>
Full article ">Figure 6 Cont.
<p>The signals for ADRs related to myocardial infarction produced by capecitabine and 5-fluorouracil. (<b>a</b>)—capecitabine (<b>b</b>)—5-fluorouracil. 5-FU—5-fluorouracil; BEV—bevacizumab; CAP—capecitabine; IRI—irinotecan; OX—oxaliplatin; PAN—panitumumab. ** <span class="html-italic">p</span> ≤ 0.01; **** <span class="html-italic">p</span> ≤ 0.0001.</p>
Full article ">Figure 7
<p>The signals in ADRs related to arrhythmias produced by capecitabine and 5-fluorouracil. (<b>a</b>)—capecitabine (<b>b</b>)—5-fluorouracil. 5-FU—5-fluorouracil; BEV—bevacizumab; CAP—capecitabine; IRI—irinotecan; OX—oxaliplatin; PAN—panitumumab. * <span class="html-italic">p</span> &lt; 0.05; ** <span class="html-italic">p</span> ≤ 0.01; **** <span class="html-italic">p</span> ≤ 0.0001.</p>
Full article ">Figure 7 Cont.
<p>The signals in ADRs related to arrhythmias produced by capecitabine and 5-fluorouracil. (<b>a</b>)—capecitabine (<b>b</b>)—5-fluorouracil. 5-FU—5-fluorouracil; BEV—bevacizumab; CAP—capecitabine; IRI—irinotecan; OX—oxaliplatin; PAN—panitumumab. * <span class="html-italic">p</span> &lt; 0.05; ** <span class="html-italic">p</span> ≤ 0.01; **** <span class="html-italic">p</span> ≤ 0.0001.</p>
Full article ">Figure 8
<p>The signals in ADRs related to heart failure produced by capecitabine and 5-fluorouracil. (<b>a</b>)—capecitabine (<b>b</b>)—5-fluorouracil. 5-FU—5-fluorouracil; BEV—bevacizumab; CAP—capecitabine; IRI—irinotecan; OX—oxaliplatin; PAN—panitumumab. **** <span class="html-italic">p</span> ≤ 0.0001.</p>
Full article ">Figure 8 Cont.
<p>The signals in ADRs related to heart failure produced by capecitabine and 5-fluorouracil. (<b>a</b>)—capecitabine (<b>b</b>)—5-fluorouracil. 5-FU—5-fluorouracil; BEV—bevacizumab; CAP—capecitabine; IRI—irinotecan; OX—oxaliplatin; PAN—panitumumab. **** <span class="html-italic">p</span> ≤ 0.0001.</p>
Full article ">Figure 9
<p>The signals in ADRs related to cardiomyopathy produced by capecitabine and 5-fluorouracil. (<b>a</b>)—capecitabine (<b>b</b>)—5-fluorouracil. 5-FU—5-fluorouracil; BEV—bevacizumab; CAP—capecitabine; IRI—irinotecan; OX—oxaliplatin; PAN—panitumumab. **** <span class="html-italic">p</span> ≤ 0.0001.</p>
Full article ">Figure 9 Cont.
<p>The signals in ADRs related to cardiomyopathy produced by capecitabine and 5-fluorouracil. (<b>a</b>)—capecitabine (<b>b</b>)—5-fluorouracil. 5-FU—5-fluorouracil; BEV—bevacizumab; CAP—capecitabine; IRI—irinotecan; OX—oxaliplatin; PAN—panitumumab. **** <span class="html-italic">p</span> ≤ 0.0001.</p>
Full article ">
14 pages, 3983 KiB  
Article
Multicellular Cancer-Stroma Spheres (CSS) for In Vitro Assessment of CAR-T Cell-Associated Toxicity
by Aigul R. Rakhmatullina, Mariya A. Zolotykh, Yuliya V. Filina, Aigul Kh. Valiullina, Ekaterina A. Zmievskaya, Dina U. Gafurbaeva, Aisylu R. Sagdeeva, Emil R. Bulatov, Albert A. Rizvanov and Regina R. Miftakhova
Cells 2024, 13(22), 1892; https://doi.org/10.3390/cells13221892 (registering DOI) - 16 Nov 2024
Viewed by 126
Abstract
CAR-T therapy has revolutionized the field of oncology, offering a promising treatment option for cancer patients. However, the significant morbidity associated with therapy-related toxicity presents a major challenge to its widespread use. Despite extensive research into the underlying mechanisms of CAR-T therapy-related toxicity, [...] Read more.
CAR-T therapy has revolutionized the field of oncology, offering a promising treatment option for cancer patients. However, the significant morbidity associated with therapy-related toxicity presents a major challenge to its widespread use. Despite extensive research into the underlying mechanisms of CAR-T therapy-related toxicity, there are still many unknowns. Furthermore, the lack of adequate in vitro models for assessing immunotoxicity and neurotoxicity further complicates the development of safer cellular therapies. Previously in our laboratory, we developed cancer-stroma spheres (CSS) composed of prostate adenocarcinoma PC3 cells and mesenchymal stem cells (MSC). Herein we present evidence that multicellular CSS could serve as a valuable in vitro model for toxicity studies related to CAR-T therapy. CSS containing CD19-overexpressing PC3M cells exhibited increased secretion of CAR-T cell toxicity-associated IL-8, MCP-1, and IP-10 in the presence of anti-CD19 CAR-T cells, compared to spheres derived from single cell types. Full article
Show Figures

Figure 1

Figure 1
<p>Microphotography of spheres formed by tumor, stroma cells, and their co-culture: (<b>A</b>) representative fluorescent microphotographs of CSS; (<b>B</b>) representative microphotographs of PC3M, MSC spheres, and CSSs treated by anti-CD19 CAR-T cells after 6 and 24 h of incubation.</p>
Full article ">Figure 2
<p>Analysis of cytotoxic effect of anti-CD19 CAR-T: (<b>A</b>) gating strategy to discriminate PC3M, MSC, and anti-CD19 CAR-T cells represented by flow cytometry plots; (<b>B</b>) proportion of PC3M and MSC in CSS; (<b>C</b>) representative flow cytometry plots with apoptotic cell gating strategy; (<b>D</b>) percent of Annexin V+ cells in PC3M spheres and CSS ( <span class="html-italic">p</span>-value is indicated as *** – ≤0.005). The data represents mean ± standard error of three independent experiments.</p>
Full article ">Figure 3
<p>Analysis of cytokine and chemokine concentrations in the conditioned media: (<b>A</b>) analysis in the conditioned media of PC3M and MSC spheres, anti-CD19 CAR-T cell culture; (<b>B</b>) analysis in the conditioned media of PC3M and MSC spheres, and complex CSSs (<span class="html-italic">p</span>-values are indicated as **—≤0.01, ***—≤0.005, ****—≤0.0001).</p>
Full article ">Figure 4
<p>Analysis of cytokine and chemokine concentrations in the conditioned media of spheres treated with anti-CD19 CAR-T cells for 6 h: (<b>A</b>) heatmap of cytokine and chemokine levels analyzed via multiplex immunoassay; (<b>B</b>) the TNFa level in the conditioned media of anti-CD19 CAR-T cell-treated PC3M spheres, and the arithmetic sum (Ʃ) of the cytokine amounts; (<b>C</b>) the MCP-1, TNFa, MIP-1b and IP-10 levels in the conditioned media of anti-CD19 CAR-T cell-treated CSSs and the arithmetic sum (Ʃ) of the cytokine amounts. *—≤0.05, ****—≤0.0001.</p>
Full article ">Figure 5
<p>Immunological response of PC3M, MSC spheres, and CSSs to CAR-T treatment. (<span class="html-italic">p</span>-values are indicated as *—≤0.05, ***—≤0.005, ****—≤0.0001).</p>
Full article ">
Back to TopTop